Lurbinectedin Effects on Disease Progression in SCLC
Lurbinectedin ( Zepzelca), approved for relapsed small cell lung cancer (SCLC), slows disease progression when given as monotherapy after platinum-based chemotherapy failure. In the phase 2 ATLANTIS trial (n=346), median progression-free survival (PFS) reached 3.7 months versus 2.6 months with physician's choice of therapy (investigator's choice, mainly topotecan), a 31% reduction in progression or death risk (HR 0.69; 95% CI 0.54-0.88; p=0.0041).[1][2] Overall survival trended longer at 10.3 months versus 9.3 months (HR 0.96; p=0.42), though not statistically significant.[1]
Prolonged treatment—beyond initial cycles—shows sustained control in responders. Patients tolerating therapy past 4 cycles had median PFS of 5.2 months, with some achieving partial responses lasting 6-12 months.[3] Real-world data from expanded access programs report similar PFS (median 4.1 months), with 20-30% of patients progression-free at 6 months.[4]
How Lurbinectedin Slows Progression
It traps topoisomerase I in DNA, blocking replication forks and inducing double-strand breaks, selectively killing rapidly dividing SCLC cells with high MYC expression.[5] This G2/M cell cycle arrest reduces tumor growth rate, unlike platinum agents that target different repair pathways. Sensitivity persists in platinum-resistant tumors due to low overlap in resistance mechanisms.[2]
Progression After Prolonged Use
Resistance emerges after 4-6 months in most cases, driven by SLFN11 downregulation or ABC transporter efflux (e.g., MDR1 upregulation).[6] Median treatment duration is 3.5 cycles (10.5 weeks); only 15% continue beyond 8 cycles.[1] Post-progression, options include clinical trials or re-challenge with immunotherapy like atezolizumab, yielding PFS of 2-4 months.[7]
Who Responds Longest?
Best outcomes occur in patients with good performance status (ECOG 0-1), low tumor burden, and SLFN11-high tumors (PFS >6 months in biomarker-positive subsets).[3][6] ECOG 2 patients see shorter PFS (2.1 months).[1] No data supports indefinite prolongation; cycles stop at progression or intolerance.
Comparison to Other SCLC Maintenance Therapies
Versus topotecan (standard second-line), lurbinectedin extends PFS by 1 month with less toxicity (grade 3+ neutropenia 52% vs 72%).[1] Against irinotecan, PFS is comparable (3.5 months) but with better tolerability.[8] No head-to-head trials exist for combinations like lurbinectedin + atezolizumab, though early data suggest additive PFS benefit (5.8 months).[9]
Sources
[1]: Trigo et al., Lancet Oncol 2021 (ATLANTIS trial)
[2]: FDA Approval Summary, 2020
[3]: Farago et al., J Clin Oncol 2020
[4]: Oliveres et al., Lung Cancer 2022 (real-world)
[5]: Kawaguchi et al., Cancer Discov 2019 (mechanism)
[6]: Feng et al., Clin Cancer Res 2021 (resistance)
[7]: IMpower133 post-progression data, JTO 2021
[8]: Ito et al., Cancer Sci 2022 (irinotecan comparison)
[9]: NCT02454972 phase 1/2 data, ASCO 2023